New strategies to reduce the risks of mRNA drug and vaccine toxicity evaluate the therapeutics at the preclinical level, bypassing the need for animal testing.

New strategies to reduce the risks of mRNA drug and vaccine toxicity evaluate the therapeutics at the preclinical level, bypassing the need for animal testing.